Terms: = Ovarian cancer AND EP300, ENSG00000100393, 2033, RP1-85F18_1, p300 AND Treatment
15 results:
1. Nanoparticle Targeting in Chemo-Resistant ovarian cancer Reveals Dual Axis of Therapeutic Vulnerability Involving Cholesterol Uptake and Cell Redox Balance.
Wang Y; Calvert AE; Cardenas H; Rink JS; Nahotko D; Qiang W; Ndukwe CE; Chen F; Keathley R; Zhang Y; Cheng JX; Thaxton CS; Matei D
Adv Sci (Weinh); 2024 Apr; 11(13):e2305212. PubMed ID: 38263873
[TBL] [Abstract] [Full Text] [Related]
2. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
[TBL] [Abstract] [Full Text] [Related]
3. ZCL-082, a boron-containing compound, induces apoptosis of non-Hodgkin's lymphoma via targeting p90 ribosomal S6 kinase 1/NF-κB signaling pathway.
Ma C; Liu M; Zhang J; Cai H; Wu Y; Zhang Y; Ji Y; Shan H; Zou Z; Yang L; Liu L; Xu H; Lei H; Liu C; Zhou L; Cao Y; Zhou H; Wu Y
Chem Biol Interact; 2022 Jan; 351():109770. PubMed ID: 34861246
[TBL] [Abstract] [Full Text] [Related]
4. Design, synthesis and biological evaluation of a novel spiro oxazolidinedione as potent p300/CBP HAT inhibitor for the treatment of ovarian cancer.
Ding H; Pei Y; Li Y; Xu W; Mei L; Hou Z; Guang Y; Cao L; Li P; Cao H; Bian J; Chen K; Luo C; Zhou B; Zhang T; Li Z; Yang Y
Bioorg Med Chem; 2021 Dec; 52():116512. PubMed ID: 34801827
[TBL] [Abstract] [Full Text] [Related]
5. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
[TBL] [Abstract] [Full Text] [Related]
6. MIR-92 stimulates VEGF by inhibiting von Hippel-Lindau gene product in epithelial ovarian cancer.
Guo FJ; Shao YP; Wang YP; Jin YM; Liu SS; Wang QY
J Biol Regul Homeost Agents; 2017 Jul-Sep,; 31(3):615-624. PubMed ID: 28952293
[TBL] [Abstract] [Full Text] [Related]
7. Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer.
Cianfrocca R; Rosanò L; Tocci P; Sestito R; Caprara V; Di Castro V; De Maria R; Bagnato A
Cell Death Differ; 2017 Oct; 24(10):1811-1820. PubMed ID: 28708138
[TBL] [Abstract] [Full Text] [Related]
8. Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression.
Cianfrocca R; Tocci P; Rosanò L; Caprara V; Sestito R; Di Castro V; Bagnato A
Oncotarget; 2016 Apr; 7(14):17790-804. PubMed ID: 26909598
[TBL] [Abstract] [Full Text] [Related]
9. Endothelin A receptor/β-arrestin signaling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy.
Rosanò L; Cianfrocca R; Tocci P; Spinella F; Di Castro V; Caprara V; Semprucci E; Ferrandina G; Natali PG; Bagnato A
Cancer Res; 2014 Dec; 74(24):7453-64. PubMed ID: 25377471
[TBL] [Abstract] [Full Text] [Related]
10. Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Coleman RL; Moon J; Sood AK; Hu W; Delmore JE; Bonebrake AJ; Anderson GL; Chambers SK; Markman M
Eur J Cancer; 2014 Jun; 50(9):1638-48. PubMed ID: 24709487
[TBL] [Abstract] [Full Text] [Related]
11. HDAC6 and ovarian cancer.
Haakenson J; Zhang X
Int J Mol Sci; 2013 May; 14(5):9514-35. PubMed ID: 23644884
[TBL] [Abstract] [Full Text] [Related]
12. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment.
Wang QE; Han C; Milum K; Wani AA
Mutat Res; 2011 Mar; 708(1-2):59-68. PubMed ID: 21310163
[TBL] [Abstract] [Full Text] [Related]
13. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
[TBL] [Abstract] [Full Text] [Related]
14. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer.
De Potter T; Flamen P; Van Cutsem E; Penninckx F; Filez L; Bormans G; Maes A; Mortelmans L
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):525-9. PubMed ID: 11914891
[TBL] [Abstract] [Full Text] [Related]
15. Primary pelvic non-Hodgkin's lymphoma.
Trenhaile TR; Killackey MA
Obstet Gynecol; 2001 May; 97(5 Pt 1):717-20. PubMed ID: 11339922
[TBL] [Abstract] [Full Text] [Related]
